Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34 Filing Table of Contents
Document/ExhibitDescriptionPagesSize
1: 10-K Annual Report HTML 1.33M
2: EX-10.27 Material Contract HTML 29K
3: EX-10.28 Material Contract HTML 33K
4: EX-10.29 Material Contract HTML 53K
5: EX-10.31 Material Contract HTML 32K
6: EX-10.32 Material Contract HTML 87K
7: EX-10.33 Material Contract HTML 269K
8: EX-10.36 Material Contract HTML 59K
9: EX-10.41 Material Contract HTML 28K
10: EX-23.1 Consent of Experts or Counsel HTML 25K
11: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
12: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
13: EX-32.1 Certification -- §906 - SOA'02 HTML 28K
28: R1 Cover HTML 91K
62: R2 Condensed Balance Sheets HTML 98K
85: R3 Unaudited Condensed Statements of Operations HTML 79K
40: R4 Unaudited Condensed Statements of Redeemable HTML 111K
Convertible Preferred Stock and Stockholders'
Equity
27: R5 Statements of Cash Flows HTML 142K
61: R6 Unaudited Condensed Statements of Redeemable HTML 32K
Convertible Preferred Stock and Stockholders'
Equity (Deficit) (Parenthetical)
84: R7 Condensed Balance Sheets - (Parenthetical) HTML 66K
38: R8 Statement of Cash Flows (Parenthetical) HTML 26K
29: R9 Organization - (Notes) HTML 35K
71: R10 Summary Of Significant Accounting Policies - HTML 147K
(Notes)
80: R11 Other Financial Information - (Notes) HTML 81K
52: R12 Borrowings - (Notes) HTML 49K
22: R13 Warrants to Purchase Common or Preferred Stock - HTML 45K
(Notes)
72: R14 Commitment and Contingencies - (Notes) HTML 52K
81: R15 Fair Value Measurements - (Notes) HTML 65K
53: R16 Redeemable Convertible Preferred Stock HTML 39K
23: R17 Stockholders' Equity (Deficit) HTML 30K
73: R18 Stock Option Plan HTML 87K
79: R19 Income Taxes HTML 102K
42: R20 Related Parties HTML 31K
30: R21 401(k) Plan HTML 27K
58: R22 Subsequent Events HTML 30K
82: R23 Summary Of Significant Accounting Policies - HTML 107K
Policies
43: R24 Summary Of Significant Accounting Policies - HTML 119K
(Tables)
31: R25 Other Financial Information - (Tables) HTML 84K
59: R26 Borrowings - (Tables) HTML 38K
83: R27 Warrants to Purchase Common or Preferred Stock - HTML 44K
(Tables)
41: R28 Commitment and Contingencies (Tables) HTML 65K
32: R29 Fair Value Measures and Disclosures (Tables) HTML 67K
26: R30 Stock Option Plan (Tables) HTML 90K
56: R31 Income Taxes (Tables) HTML 103K
78: R32 Organization - (Details) HTML 51K
70: R33 Summary Of Significant Accounting Policies - HTML 52K
Narrative (Details)
25: R34 Summary Of Significant Accounting Policies - HTML 52K
Revenue by Major Payers (Details)
54: R35 Summary Of Significant Accounting Policies - HTML 38K
Disaggregation of Revenue (Details)
77: R36 Summary Of Significant Accounting Policies - Cash, HTML 35K
cash equivalents and restricted cash (Details)
69: R37 Summary Of Significant Accounting Policies - HTML 36K
Securities (Details)
24: R38 Other Financial Information - Narrative (Details) HTML 32K
57: R39 Other Financial Information - Prepaid expenses HTML 38K
(Details)
36: R40 Other Financial Information - Property and HTML 45K
equipment (Details)
45: R41 Other Financial Information - Accrued liabilities HTML 48K
(Details)
88: R42 Borrowings - Narrative (Details) HTML 78K
66: R43 Borrowings - Future minimum payments (Details) HTML 49K
34: R44 Warrants to Purchase Common or Preferred Stock - HTML 36K
Narrative (Details)
44: R45 Warrants to Purchase Common or Preferred Stock - HTML 40K
Outstanding warrants (Details)
87: R46 Commitment and Contingencies - Narrative (Details) HTML 55K
65: R47 Commitment and Contingencies - Minimum annual HTML 69K
lease payments under non-cancelable lease
arrangements (Details)
33: R48 Fair Value Measurements - Fair value measurement HTML 45K
(Details)
46: R49 Fair Value Measurements- Fair value level 3 HTML 42K
(Details)
49: R50 Redeemable Convertible Preferred Stock (Details) HTML 83K
19: R51 Stockholders' Equity (Deficit) (Details) HTML 49K
67: R52 Stock Option Plan - Narrative (Details) HTML 71K
74: R53 Stock Option Plan - Stock Option Activity HTML 83K
(Details)
51: R54 Stock Option Plan - Fair Value Assumptions HTML 46K
(Details)
20: R55 Stock Option Plan - Stock-Based Compensation HTML 34K
Expense (Details)
68: R56 Stock Option Plan - Common Stock Reserved For HTML 35K
Future Issuance (Details)
75: R57 Income Taxes (Details) HTML 39K
48: R58 Income Taxes - Components of Income Tax Expense HTML 48K
(Benefit) (Details)
21: R59 Income Taxes - Reconciliation of Effective Income HTML 47K
Tax Rate (Details)
63: R60 Income Taxes - Reconciliation of Deferred Tax HTML 61K
Assets and Liabilities (Details)
86: R61 Income Taxes - Change In Valuation Allowance HTML 31K
(Details)
47: R62 Related Parties (Details) HTML 45K
37: R63 401(k) Plan (Details) HTML 28K
64: R64 Subsequent Events (Details) HTML 42K
39: R9999 Uncategorized Items - exdx-20191231.htm HTML 25K
55: XML IDEA XML File -- Filing Summary XML 147K
35: XML XBRL Instance -- exdx-20191231_htm XML 1.84M
50: EXCEL IDEA Workbook of Financial Reports XLSX 87K
15: EX-101.CAL XBRL Calculations -- exdx-20191231_cal XML 235K
16: EX-101.DEF XBRL Definitions -- exdx-20191231_def XML 679K
17: EX-101.LAB XBRL Labels -- exdx-20191231_lab XML 1.77M
18: EX-101.PRE XBRL Presentations -- exdx-20191231_pre XML 1.03M
14: EX-101.SCH XBRL Schema -- exdx-20191231 XSD 172K
76: JSON XBRL Instance as JSON Data -- MetaLinks 364± 562K
60: ZIP XBRL Zipped Folder -- 0001274737-20-000026-xbrl Zip 733K
I am pleased to confirm our offer for you to join Exagen Inc. as Chief Medical Officer with a start date of 3/24/2020. This offer is contingent upon the successful completion of a pre-employment background check and proof of work eligibility. This is an exempt position
and will report to Ron Rocca. We are offering you a bi-weekly salary of $14,615.38 ($380,000.00 annualized).
You are eligible for achievement incentive compensation which will be contingent on you meeting certain performance goals. Your annual incentive compensation will be worth 45% of your annual salary and will be pro-rated in the first year to start date. In addition, you will receive 100,000 options to purchase the company's common stock contingent upon the approval of the Exagen Board of Directors, the timing of which will also be subject to the Board's discretion.
You are eligible to participate in the Exagen benefits program, a summary of which you will receive under separate cover. You will accrue 3 weeks (or 120 hours) of paid time off a year in addition to the ten holidays currently recognized
by Exagen.
Exagen currently has a safe harbor 40l(k) plan and contributes an amount equal to 3% of your annual income into your 40l(k). There is no vesting period in the 40l(k). You must be employed by Exagen for 3 months before becoming eligible to participate in the 40l(k).
Employment at Will: This letter is intended to communicate certain terms and conditions of employment with Exagen Inc. but is not intended to be and should not be considered an employment contract. Your employment is not for a specific duration and may be terminated by you or Exagen Inc. at any time, for any reason or for no reason whatsoever, with or without notice and with or without cause unless otherwise specified by law. Your employment is "at will." The "at will" status of your employment may not be
altered except by a separate written contract signed by the Chief Financial Officer of Exagen Inc. No one other than the Chief Financial Officer has the authority to enter into an employment contract with you.
I look forward to working with you as a member of the Exagen team. We are excited about the contributions you will make to the success of our company. If you have any further questions, please do not hesitate to contact me.
